archive-au.com » AU » C » CSL.COM.AU

Total: 502

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • CSL Ltd is a leader in plasma protein biotherapeutics
    in Oxford regarding the therapeutic powers of penicillin CSL staff member Val Bazeley is recalled from the armed services to supervise CSL s production of the drug By February 1944 a CSL production team is supplying the needs of the Australian forces and some of the Americans serving in the Pacific Using CSL supplies Australia will be the first country in the world to supply penicillin freely to civilians Vials of early penicillin issued by the Commonwealth Serum Laboratories 1946 Europe s First Human Plasma Fractionation Behringwerke is the first company in Europe to begin fractionating plasma proteins from human plasma on an industrial scale 1949 Zentrallaboratorium Blutspendedienst Established ZLB is established in Bern as a department of the Swiss Red Cross and holds its first blood donor sessions in Switzerland 1952 Blood Fractionation Commences at CSL Bioplasma Blood fractionation based on the method developed by Dr Edwin Cohn of Harvard University begins at CSL 1953 CSL Introduced Triple Antigen Vaccine Triple Antigen vaccine for the immunisation of infants and young children against tetanus diphtheria and whooping cough and Immune Serum Globulin 1950 s Advertisment 1954 First Albumin Issued by CSL CSL first issues Albumin 1956 Biological Products Booklet 1955 1956 Poliomyelitis Vaccine Production Commences at CSL Epidemics of poliomyelitis or infantile paralysis were experienced in Australia and overseas from the beginning of the 20th century In 1937 38 Australia s worst polio epidemic occurred affecting thousands of children CSL devoted resources to the study of poliomyelitis throughout the 1920s 30s 40s and 50s In 1955 the work of Jonas Salk at the University of Pittsburgh brought the possibility of a vaccine closer In 1954 a CSL officer was sent to Salk s laboratory as his first assistant The officer was Val Bazeley later to become Director of CSL He

    Original URL path: http://www.csl.com.au/about/history/1940-1959.htm (2014-01-05)
    Open archived version from archive


  • CSL Ltd is a leader in plasma protein biotherapeutics
    Our Products Research and Development Business Development Investors Corporate Responsibility Careers Newsroom Contact CSL Home About CSL 1960 1979 Also in this section 1900 1919 1920 1939 1940 1959 1980 1999 2000 present 1961 CSL Incorporated as a Commonwealth Statutory Authority CSL is incorporated as a Commonwealth Statutory Authority under the control of a Board of Commissioners CSL first issues haemophiliacs with anti haemophilic globulin produced from plasma 1962 First Polyvalent Snake Antivenom Released CSL releases the first polyvalent snake antivenom for the treatment of all Australian and Papua New Guinean venomous snake bites CSL Bioplasma provides products to New Zealand from New Zealand plasma 1966 1967 Rh D Immunoglobulin Introduced Rh D Immunoglobulin produced from plasma is introduced for haemolytic disease in newborns Australia is the first country in the world to issue this product on a national basis 1978 Bluetongue Vaccine Investigated CSL uses its recently completed maximum security laboratory for urgent investigative work into bluetongue vaccine following isolation of the virus in Australia 1981 First Pasteurised Factor VIII Therapy Produced World s First Pasteurised Factor VIII Therapy Haemate human plasma coagulation factor VIII von Willebrand factor complex is first marketed in Europe for the treatment of patients

    Original URL path: http://www.csl.com.au/about/history/1960-1979.htm (2014-01-05)
    Open archived version from archive

  • CSL Ltd is a leader in plasma protein biotherapeutics
    funnel web spider In recognition of his achievements he was awarded the AMA Prize for Medical Research in 1977 and the James Cook Medal of the Royal Society of NSW in 1984 A prolific author he published over 300 articles and book chapters throughout his career Struan Sutherland was honoured posthumously in the 2002 Australia Day awards as an Officer of the Order of Australia 1983 Manufacturing of GLANVAC Vaccine CSL begins manufacturing GLANVAC vaccine for the prevention of clostridial diseases and cheesy gland in sheep 1991 CSL Limited is Incorporated CSL Limited is incorporated as a Public Company in April 1991 under the Corporations Law All shares are held by the Commonwealth Government Incoming MD CEO Dr Brian McNamee states our main aim is to contribute to national health and wealth by building a great and independent Australian company 1992 CSL signs agreement with Merck to Produce Child Vaccines CSL signs an agreement with Merck Sharp Dohme Australia Pty Ltd and Merck Co Inc to develop combination vaccines for children in Australia New Zealand and the Asia Pacific region CSL Bioplasma commences toll manufacturing for Malaysia 1993 Agreement with Commonwealth Government to Produce Plasma derived Products CSL enters a 10 year agreement with the Commonwealth for the manufacture and supply of a range of plasma derived products for Australians Production commences at CSL s new plasma products facility CSL Bioplasma in Broadmeadows CSL commences involvement in two Cooperative Research Centres developing and commercialising Australian innovative technology 1994 Public Listed in Australian Stock Exchange Following a public float CSL is listed on the Australian Stock Exchange on 30th May 1994 Official sale date 3 June 1994 CSL s Broadmeadows Bioplasma plant is opened The chromatographic albumin plant included in the facility is the largest in the world CSL acquires US

    Original URL path: http://www.csl.com.au/about/history/1980-1999.htm (2014-01-05)
    Open archived version from archive

  • CSL Ltd is a leader in plasma protein biotherapeutics
    doubling the production of influenza vaccine to supply the demands in the Northern and Southern hemispheres CSL introduces Menjugate to the Australian market Menjugate is a conjugated meningococcal C vaccine licensed from Chiron Corporation Opening of first regional office in Hong Kong 2003 CSL s thiomersal free Influenza Vaccine Launched Launch of CSL s thiomersal free Fluvax influenza vaccine CSL Bioplasma s new purpose built nucleic acid testing NAT laboratory commissioned CSL obtains US Human Papillomavirus Patent 2004 CSL Goes Global CSL completes the acquisition of Aventis Behring combining it with ZLB Bioplasma to create ZLB Behring now known as CSL Behring a global leader in plasma therapeutics Sale of Animal Health business to Pfizer Inc resulted in net proceeds of 161 6 million 2005 GARDASIL A Vaccine Against Cervical Cancer CSL s collaboration with Merck Co Inc and the University of Queensland to develop a cervical cancer vaccine succeeds The product enters Phase III clinical trials and in 2006 receives FDA approval 2006 CSL acquires Zenyth Therapeutics and Vivaglobin approved in U K and U S Vivaglobin is licensed for use in the U K and U S for adults and children who require antibody replacement due to primary immunodeficiency CSL acquires Zenyth Therapeutics Limited strengthening CSL s investment in developing products based on recombinant monoclonal antibodies 2007 Privigen approved in the U S Privigen is the first proline stabilised liquid intravenous immunoglobulin IVIg ready for immediate use requiring no refrigeration or reconstitution Privigen approved by FDA Biologics License Application BLA was filed with the FDA for the registration of CSL s influenza vaccine in the U S 2008 Privigen launched in the U S CSL signed a five year agreement with the Canadian Blood Service to fractionate Canadian plasma and supply a broad range of plasma products CSL

    Original URL path: http://www.csl.com.au/about/history/2000-present.htm (2014-01-05)
    Open archived version from archive

  • CSL Limited's Immunohaematology business
    on human red cells Anti k Cellano Phenotyping Reagent Used to detect the presence of the k Cellano antigen on human red cells Anti Kp a Phenotyping Reagent Used to detect the presence of the Kp a antigen on human red cells B Bovine Albumin 30 Solution Supplementary Reagent Used to enhance the agglutination of red cells in antibody detection tests C Celpresol Supplementary Reagent Designed for the preservation suspension and resuscitation of human red blood cells Celpresol LISS Supplementary Reagent Designed for the preservation suspension and resuscitation of human red blood cells Controcell 2 EU and US only Reagent Red Blood Cells Designed to control standardise and validate all routine immunohaematology tests Controcell 4 EU and US only Reagent Red Blood Cells Designed to control standardise and validate all routine immunohaematology tests Cord Cells 3 Reagent Red Blood Cells Used for confirming the presence of anti I in an antibody identification procedure E Epiclone 2 Anti D IgM IgG RhD Reagent Designed for routine RhD typing of human red cells Epiclone 2 Anti D IgM RhD Reagent Used to detect the presence of RhD positive human red cells Epiclone AHG Poly Anti Human Globulin Reagent Used for detection of clinically relevant IgG subtypes Epiclone Anti A ABO Reagent Used to detect the presence of the A antigen on human red cells Epiclone Anti A B ABO Reagent Used to detect the presence of the A and B antigens on human red cells Epiclone Anti B ABO Reagent Used to detect the presence of the B antigen on human red cells Epiclone Anti c Phenotyping Reagent Used to detect the presence of the c antigen on human red cells Epiclone Anti C Phenotyping Reagent Used to detect the presence of the C antigen on human red cells Epiclone Anti C w Phenotyping Reagent Used to detect the presence of the C w antigen on human red cells Epiclone Anti C3d Anti Human Globulin Reagent Used to only detect the clinically relevant complement components in relation to Anti C3d Epiclone Anti DCE Phenotyping Reagent Used to detect the presence of the D C and E antigens on human red cells Epiclone Anti e Phenotyping Reagent Used to detect the presence of the e antigen on human red cells Epiclone Anti E Phenotyping Reagent Used to detect the presence of the E antigen on human red cells Epiclone Anti Jk a Phenotyping Reagent Used to detect the presence of the Jk a antigen on human red cells Epiclone Anti Jk b Phenotyping Reagent Used to detect the presence of the Jk b antigen on human red cells Epiclone Anti K Kell Phenotyping Reagent Used to detect the presence of the K antigen on human red cells Epiclone Anti Le a Phenotyping Reagent Used to detect the presence of the Le a antigen on human red cells Epiclone Anti Le b Phenotyping Reagent Used to detect the presence of the Le b antigen on human red cells Epiclone Anti M Phenotyping Reagent Used

    Original URL path: http://www.csl.com.au/businesses/csl-biotherapies-immunohaematology/products.htm (2014-01-05)
    Open archived version from archive

  • The resources of Immunohaematology
    Service ARCBS National Blood Authority NBA Australian and New Zealand Society of Blood Transfusion ANZSBT Australian Institute of Medical Scientists AIMS New Zealand Blood Service NZBS Royal College of Pathologists of Australasia RCPA International Society of Blood Transfusion ISBT American Association of Blood Banks AABB American Red Cross There are a number of international organisations that represent individuals and institutions involved in immunohaematology blood banking and transfusion medicine Broadly speaking

    Original URL path: http://www.csl.com.au/businesses/csl-biotherapies-immunohaematology/resources.htm (2014-01-05)
    Open archived version from archive

  • Regulatory
    IH Portal Home Our Businesses bioCSL bioCSL Immunohaematology Regulatory Regulatory Related sites Therapeutic Goods Administration TGA National Association of Testing Authorities Australia NATA US Food and Drug Administration FDA International Organization of Standardization ISO There is an increasing requirement for regulatory compliance across all disciplines in the pathology industry As immunohaematology involves the diagnostic testing for the transfusion of a life saving therapeutic product blood it can be expected that the regulatory compliance requirements will continue to increase over time Principles of Quality Control and Quality Assurance Quality Control QC involves the management of the testing process It includes controlling the testing environment to ensure that tests are reproducible accurate and sensitive QC of reagents should be a regular part of immunohaematology laboratory testing and should encompass tests for avidity specificity and sensitivity While reagent QC is vital it will not control and monitor all aspects of the testing process For QC to be effective it should be capable of detecting monitoring and correcting all potential errors and be an integral part of a managed Quality Assurance QA system QA involves the management monitoring and control of the entire process of providing a service In blood transfusion this includes all

    Original URL path: http://www.csl.com.au/businesses/csl-biotherapies-immunohaematology/regulatory.htm (2014-01-05)
    Open archived version from archive

  • Snakebite Management
    Healthcare Professionals Additional resources are available in the Snakebite Management portal Please email ih biocsl com au with your AHPRA registration number for login details Existing Customers Additional resources are available in the IH Australian Customer portal Contact bioCSL Immunohaematology Snakebite Management Poster Set bioCSL has developed a Snakebite Management poster set to support the use of effective first aid in the management of snakebite The posters are designed to

    Original URL path: http://www.csl.com.au/businesses/csl-biotherapies-immunohaematology/snakebite-management.htm (2014-01-05)
    Open archived version from archive